Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis

Kimberly Spooner,1–3 Thomas Hong,1,2 Wijeyanthy Wijeyakumar,1–3 Andrew A Chang1–3 1Sydney Retina Clinic & Day Surgery, 2Sydney Institute of Vision Science, Sydney, 3Save Sight Institute, Department of Ophthalmology, University of Sydney, Camperdown, NSW, Austra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Spooner K, Hong T, Wijeyakumar W, Chang AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Treatment resistance macular degeneration retina aflibercept anti-VEGF Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d0231c68719f4667afef0f54a0b34221
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0231c68719f4667afef0f54a0b34221
record_format	dspace
spelling	oai:doaj.org-article:d0231c68719f4667afef0f54a0b342212021-12-02T04:19:16ZSwitching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis1177-5483https://doaj.org/article/d0231c68719f4667afef0f54a0b342212017-01-01T00:00:00Zhttps://www.dovepress.com/switching-to-aflibercept-among-patients-with-treatment-resistant-neova-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kimberly Spooner,1–3 Thomas Hong,1,2 Wijeyanthy Wijeyakumar,1–3 Andrew A Chang1–3 1Sydney Retina Clinic & Day Surgery, 2Sydney Institute of Vision Science, Sydney, 3Save Sight Institute, Department of Ophthalmology, University of Sydney, Camperdown, NSW, Australia Purpose: To systematically review anatomical and functional outcomes subsequent to switching from bevacizumab/ranibizumab to aflibercept monotherapy in patients with treatment-resistant neovascular age-related macular degeneration (nAMD). Design: Systematic review and meta-analysis. Methods: Medline, PubMed, Embase, and Cochrane databases were searched up to July 2016 for available scientific literature which met inclusion criteria. Eligible studies reported visual and anatomical outcomes with at least 6 months of follow-up among patients with nAMD and persistent or resistant exudative fluid despite previous anti-vascular endothelial growth factor (VEGF) therapy (bevacizumab and/or ranibizumab) and were switched to aflibercept monotherapy. Mean changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were pooled using random-effects models with 95% confidence intervals (CIs). Results: Of 82 papers reviewed, 28 studies met inclusion criteria of this review. Pooled results showed a small mean improvement in BCVA at 6 and 12 months following switching (1.11 letters, 95% CI -0.25 to 2.46, P=0.17 and 0.63 letters, 95% CI -0.26 to 1.52, P=0.17, respectively). There was a significant improvement in mean CRT following switching (-61.90 µm, 95% CI -77.10 to -46.80, P<0.001 and -50.00 µm, 95% CI -63.20 to -36.80, P<0.001 at 6 and 12 months, respectively). Conclusion: Pooled analysis demonstrated significantly improved anatomical outcomes; however, visual function remained stable, having a comparable effect to other anti-VEGF agents in preservation of vision. These patients had poorly responsive chronic disease with limited potential for visual recovery. Switching to aflibercept with frequent monitoring may be a suitable option for patients who have developed treatment resistance. Keywords: anti-vascular endothelial growth factor, macular degeneration, treatment resistance, meta-analysis, afliberceptSpooner KHong TWijeyakumar WChang AADove Medical PressarticleTreatment resistancemacular degenerationretinaafliberceptanti-VEGFOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 161-177 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Treatment resistance macular degeneration retina aflibercept anti-VEGF Ophthalmology RE1-994
spellingShingle	Treatment resistance macular degeneration retina aflibercept anti-VEGF Ophthalmology RE1-994 Spooner K Hong T Wijeyakumar W Chang AA Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
description	Kimberly Spooner,1–3 Thomas Hong,1,2 Wijeyanthy Wijeyakumar,1–3 Andrew A Chang1–3 1Sydney Retina Clinic & Day Surgery, 2Sydney Institute of Vision Science, Sydney, 3Save Sight Institute, Department of Ophthalmology, University of Sydney, Camperdown, NSW, Australia Purpose: To systematically review anatomical and functional outcomes subsequent to switching from bevacizumab/ranibizumab to aflibercept monotherapy in patients with treatment-resistant neovascular age-related macular degeneration (nAMD). Design: Systematic review and meta-analysis. Methods: Medline, PubMed, Embase, and Cochrane databases were searched up to July 2016 for available scientific literature which met inclusion criteria. Eligible studies reported visual and anatomical outcomes with at least 6 months of follow-up among patients with nAMD and persistent or resistant exudative fluid despite previous anti-vascular endothelial growth factor (VEGF) therapy (bevacizumab and/or ranibizumab) and were switched to aflibercept monotherapy. Mean changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were pooled using random-effects models with 95% confidence intervals (CIs). Results: Of 82 papers reviewed, 28 studies met inclusion criteria of this review. Pooled results showed a small mean improvement in BCVA at 6 and 12 months following switching (1.11 letters, 95% CI -0.25 to 2.46, P=0.17 and 0.63 letters, 95% CI -0.26 to 1.52, P=0.17, respectively). There was a significant improvement in mean CRT following switching (-61.90 µm, 95% CI -77.10 to -46.80, P<0.001 and -50.00 µm, 95% CI -63.20 to -36.80, P<0.001 at 6 and 12 months, respectively). Conclusion: Pooled analysis demonstrated significantly improved anatomical outcomes; however, visual function remained stable, having a comparable effect to other anti-VEGF agents in preservation of vision. These patients had poorly responsive chronic disease with limited potential for visual recovery. Switching to aflibercept with frequent monitoring may be a suitable option for patients who have developed treatment resistance. Keywords: anti-vascular endothelial growth factor, macular degeneration, treatment resistance, meta-analysis, aflibercept
format	article
author	Spooner K Hong T Wijeyakumar W Chang AA
author_facet	Spooner K Hong T Wijeyakumar W Chang AA
author_sort	Spooner K
title	Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
title_short	Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
title_full	Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
title_fullStr	Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
title_full_unstemmed	Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
title_sort	switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/d0231c68719f4667afef0f54a0b34221
work_keys_str_mv	AT spoonerk switchingtoafliberceptamongpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationasystematicreviewwithmetaanalysis AT hongt switchingtoafliberceptamongpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationasystematicreviewwithmetaanalysis AT wijeyakumarw switchingtoafliberceptamongpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationasystematicreviewwithmetaanalysis AT changaa switchingtoafliberceptamongpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationasystematicreviewwithmetaanalysis
_version_	1718401336590991360

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis

Ejemplares similares